Free tool
FAERS Monitor: Fensolvi Kit
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213150 or its brand name (Fensolvi Kit, Leuprolide Acetate). Reports on generic versions are filed under their own applications.
Reports
7,739
Serious
6,129
79% of reports
Hospitalization
2,981
Death reported
1,131
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use529
- drug ineffective448
- fatigue393
- hot flush292
- fall282
- asthenia276
- death268
- pneumonia249
- prostate cancer236
- nausea228
- anaemia222
- intercepted product preparation error213
- diarrhoea203
- diabetes mellitus194
- prostatic specific antigen increased192
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 83 |
| 2005 | 96 |
| 2006 | 85 |
| 2007 | 119 |
| 2008 | 351 |
| 2009 | 153 |
| 2010 | 237 |
| 2011 | 236 |
| 2012 | 301 |
| 2013 | 60 |
| 2014 | 56 |
| 2015 | 138 |
| 2016 | 113 |
| 2017 | 126 |
| 2018 | 152 |
| 2019 | 160 |
| 2020 | 207 |
| 2021 | 530 |
| 2022 | 930 |
| 2023 | 953 |
| 2024 | 863 |
| 2025 | 973 |
| 2026 | 817 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,420 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intercepted product preparation errorSignal | 213 | 47.8 | 41.9 | 9,560 |
| prostatic specific antigen increasedSignal | 192 | 38.4 | 33.4 | 6,863 |
| hot flushSignal | 292 | 10.6 | 9.4 | 2,519 |
| prostate cancerSignal | 236 | 8.0 | 7.1 | 1,439 |
| diabetes mellitusSignal | 194 | 6.9 | 6.0 | 980 |
| anaemiaSignal | 222 | 3.2 | 2.8 | 329 |
| fallSignal | 282 | 2.3 | 2.1 | 210 |
| pneumoniaSignal | 249 | 2.1 | 1.9 | 143 |
| asthenia | 276 | 2.0 | 1.8 | 138 |
| off label use | 529 | 1.6 | 1.5 | 138 |
| fatigue | 393 | 1.4 | 1.2 | 41 |
| drug ineffective | 448 | 0.9 | 0.8 | 3 |
| diarrhoea | 203 | 0.9 | 0.7 | 5 |
| death | 268 | 0.8 | 0.8 | 8 |
| nausea | 228 | 0.8 | 0.7 | 14 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.